Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Heron Therapeutics (HRTX) PT Lowered to $20 at Cantor Fitzgerald
March 1, 2022 7:22 AM ESTCantor Fitzgerald analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $20.00 (from $26.00) while maintaining a Neutral rating.
... MoreHeron Therapeutics (HRTX) PT Lowered to $13 at Cowen
March 1, 2022 6:54 AM ESTCowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $13.00 (from $31.00) while maintaining an Outperform rating following disappointing Q4 results.
The analyst commented, "Heron reported disappointing 4Q21 earnings with Zynrelef reaching sales of only $0.8MM (-61% Q/Q). We... More
Heron Therapeutics (HRTX) Tops Q4 EPS by 4c
February 28, 2022 4:28 PM ESTHeron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20.66 million versus the consensus estimate of $25.59 million.
For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.
... More